Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01168973 · ClinicalTrials.gov registry record · Phase 3
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,253
- Enrollment target
NCT01168973: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01168973 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,253 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01168973, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,253 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.
Primary Outcome
Overall survival was the time from randomization until the date of death from any cause. Participants who were alive at the end of the follow-up period (or lost to follow-up) were censored on the last date the participant was known to be alive.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Ramucirumab
- DRUG Placebo (for Ramucirumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,253 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
What the finished NCT01168973 record still lists
NCT01168973 is an interventional study that assigns participants to a tested intervention. Its 1,253 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01168973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01168973 about?
NCT01168973 is a clinical study titled "A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy". The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.
What is the current status of trial NCT01168973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,253 participants. The study started on 2010-12. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01168973?
The interventions under investigation include: Docetaxel (DRUG), Ramucirumab (BIOLOGICAL), Placebo (for Ramucirumab) (DRUG).
Who is sponsoring clinical trial NCT01168973?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01168973's enrollment target sits among peer trials
1,253 206th of 2000 higher than 1,795 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia